



ATTORNEY'S DOCKET NO: A90752/70001 (HCL)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Gregory L. Stahl et al.
Serial No.: 09/464,303
Filed: December 15, 1999
For: METHODS AND PRODUCTS FOR REGULATING LECTIN COMPLEMENT
PATHWAY ASSOCIATED COMPLEMENT ACTIVATION
Examiner: Amy DeCloux
Art Unit: 1644

RECEIVED
SEP 18 2002
TECH CENTER 1600/2321

COPY OF PAPERS
ORIGINALLY FILED

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Box AF, Commissioner for Patents, Washington, D.C. 20231, on the 9th day of September, 2002.

Helen C. Lockhart

Box AF
Commissioner for Patents
Washington, D.C. 20231

AMENDMENT

Sir:

This is in response to the Final Office Action (Paper No. 13) mailed from the United States Patent and Trademark Office on May 7, 2002.

In the Claims:

Please amend the claims as follows:

18. (Twice Amended) A composition, comprising an MBL inhibitor, wherein the MBL inhibitor is an isolated binding peptide that selectively binds to a human MBL epitope and that inhibits LCP associated complement activation, wherein the isolated MBL binding peptide has an MBL binding CDR3 region or a functional variant thereof of a monoclonal antibody produced by a hybridoma cell line selected from the group consisting of hybridoma cell line_(3F8), hybridoma cell line_(2A9), and hybridoma cell line_(hMBL1.2) deposited under ATCC accession numbers HB-12621, HB-12620, and HB-12619 respectively.

Ok to
enter
As
Sub
B+C
9/19/02